阿托伐他汀钙/非诺贝特(Atorvastatin Calcium/Fenofibrate) - 药物靶点：HMGCR x PPARα_专利_临床

概要

基本信息

药物类型

小分子化药

别名

AtorFen、Atorvastatin/fenofibrate、LCP-AtorFen

靶点

HMGCR x PPARα

作用方式

抑制剂、激动剂

作用机制

HMG-CoA reductase抑制剂(羟甲基戊二酰辅酶A合酶抑制剂)、PPARα激动剂(过氧化物酶体增长因子活化受体α激动剂)

治疗领域

内分泌与代谢疾病

在研适应症-

非在研适应症

血脂障碍

原研机构

Veloxis Pharmaceuticals A/S

在研机构-

非在研机构

Life Cycle Pharma A/S

Veloxis Pharmaceuticals A/S

最高研发阶段无进展临床2/3期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

结构/序列

分子式C66H76CaF2N4O13

InChIKeyHIZONJHAVINWOX-NIJVSVLQSA-N

CAS号344423-98-9

查看全部结构式(2)

关联

3

项与阿托伐他汀钙/非诺贝特相关的临床试验

NCT04882293

/ Unknown status临床3期

Confirmatory Study of the Efficacy and Safety of the Fixed-dose Combination Atorvastatin / Fenofibrate Versus Atorvastatin on the Lipid Profile of Patients With Type 2 Diabetes (T2D) and Dyslipidaemia (DLP).

Phase IIIb, randomized, longitudinal, prospective, multicenter study to evaluate the efficacy and safety of the fixed-dose combination atorvastatin / fenofibrate versus atorvastatin on the lipid profile of patients with type 2 diabetes and dyslipidemia.

开始日期2022-02-15

申办/合作机构

Laboratorios Silanes SA de CV

NCT00664859

/ Completed临床2/3期

A 12-Month, Open-Label, Extension Study of the Safety and Efficacy of LCP-AtorFen in Subjects With Dyslipidemia

The current study is designed to test the long-term (12-month) safety and efficacy of LCP-AtorFen, a combination of atorvastatin and fenofibrate, in patients with dyslipidemia

开始日期2007-10-01

申办/合作机构

Veloxis Pharmaceuticals A/S

NCT00504829

/ Completed临床2期

A 12-Week, Multi-Center, Double-Blind, Randomized, Parallel-Group Study, Followed by a 12 Month Extension Study, of the Efficacy and Safety of LCP-AtorFen in Subjects With Dyslipidemia

The current study is designed to test the efficacy, safety and tolerability of LCP-AtorFen, a combination of atorvastatin and fenofibrate.

开始日期2007-07-01

申办/合作机构

Veloxis Pharmaceuticals A/S

100 项与阿托伐他汀钙/非诺贝特相关的临床结果

登录后查看更多信息

100 项与阿托伐他汀钙/非诺贝特相关的转化医学

登录后查看更多信息

100 项与阿托伐他汀钙/非诺贝特相关的专利（医药）

登录后查看更多信息

1

项与阿托伐他汀钙/非诺贝特相关的新闻（医药）

2007-11-20

·BioSpace

LifeCycle Pharma Completes Patient Enrollment in Phase II Clinical Trial of LCP-AtorFen for the Treatment of Mixed Dyslipidemia, Initiates 52-Week Open Label Extension Study

H0RSHOLM, Denmark--(BUSINESS WIRE)--LifeCycle Pharma A/S (OMX: LCP) (the “Company” or “LCP”), an emerging specialty pharmaceutical company, today announced that it has completed patient enrollment in its Phase II clinical trial of LCP-AtorFen for the treatment of mixed dyslipidemia, which commenced in July 2007 to compare LCP-AtorFen, the Company’s fixed-dose combination product candidate of atorvastatin and lowest dose fenofibrate, with Lipitor® (40 mg atorvastatin calcium tablets) and Tricor® (145mg fenofibrate tablets). In addition, the Company announced that it has initiated a 52-week, open-label extension study in order to capture additional safety and efficacy data on the use of LCP AtorFen in patients with mixed dyslipidemia.

合作

100 项与阿托伐他汀钙/非诺贝特相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	-	-	DB05769

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
血脂障碍	临床3期	美国	Veloxis Pharmaceuticals A/S	2007-10-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT00664859 (CTgov)	临床2/3期	血脂障碍	140	LCP-AtorFen (LCP-AtorFen 40/100mg)	網簾齋齋蓋憲鬱觸膚餘(壓襯襯夢鹹選築鑰製鹹) = 鬱膚襯膚鹹製鑰壓顧醖齋範鹽醖襯製遞膚糧築 (觸鹹鏇醖選鑰簾鏇淵簾, 13.58) 更多	-	2020-03-24
				Atorvastatin (Atorvastatin 40 mg)	網簾齋齋蓋憲鬱觸膚餘(壓襯襯夢鹹選築鑰製鹹) = 願壓壓淵齋選糧餘鹽壓齋範鹽醖襯製遞膚糧築 (觸鹹鏇醖選鑰簾鏇淵簾, 18.18) 更多
NCT00504829 (CTgov)	临床2期	血脂障碍	220	LCP-AtorFen (LCP-AtorFen 40/100mg)	糧鹹願簾築齋壓壓鑰艱(蓋膚醖鹹齋齋範製構艱) = 衊淵遞醖築齋簾艱範糧衊獵鑰憲憲糧鑰繭積鹹 (鬱鹽壓壓壓廠糧餘鹹鹹, 16.2) 更多	-	2020-02-05
				Atorvastatin (Atorvastatin 40mg)	糧鹹願簾築齋壓壓鑰艱(蓋膚醖鹹齋齋範製構艱) = 簾衊餘製鏇鏇膚遞蓋願衊獵鑰憲憲糧鑰繭積鹹 (鬱鹽壓壓壓廠糧餘鹹鹹, 17.3) 更多